A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

This early-phase study tests a drug combination — gemcitabine (an established chemotherapy) plus nab-sirolimus (a newer drug that targets a specific cell growth pathway) — in patients with advanced soft tissue sarcomas, particularly leiomyosarcoma or sarcomas with specific gene mutations (TSC1 or TSC2). The goal is to establish safe dosing. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with leiomyosarcoma or another soft tissue sarcoma with TSC1 or TSC2 gene mutations - Your cancer has spread or cannot be surgically removed, and standard treatments are no longer working - You have at least one measurable tumor on imaging - Your liver, kidney, and blood counts are within acceptable ranges **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have active brain metastases (cancer that has spread to the brain) that are not controlled - You have serious heart problems or an active infection - You have had gemcitabine within the past 12 months with disease progression while on it Talk to your doctor to see if this trial is right for you.